COGT
Cogent Biosciences, Inc.
Latest Form 4:Sale$242.6MbyFairmount Funds Management LLC (Director) · filed Mar 31, 2026
Cogent Biosciences, Inc. (COGT) has 12 SEC Form 4 filings (26 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: May 21, 2026.
Insiders have net sold $254.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Andrew R. Robbins
- Employees:258
- HQ:Waltham, MA, US
- IPO:2018-03-29
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$254.8M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$6.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 7,000,000 | $242.6M | Mar 31 | SEC ↗ | |
Green John L.First filing | Chief Financial Officer | Sale | 77,000 | $3.0M | Dec 30 | SEC ↗ |
Kearns EvanFirst filing | Chief Legal Officer | Sale | 65,000 | $2.5M | Dec 30 | SEC ↗ |
Robinson John EdwardFirst filing | Chief Scientific Officer | Sale | 90,000 | $3.5M | Dec 30 | SEC ↗ |
Sachs JessicaFirst filing | Chief Medical Officer | Sale | 82,642 | $3.2M | Dec 30 | SEC ↗ |
Related companies
Cogent Biosciences, Inc. is in the Healthcare sector.